



(11) **EP 3 275 901 A8**

(12) **CORRECTED EUROPEAN PATENT APPLICATION**

(15) Correction information:

**Corrected version no 1 (W1 A1)**  
**Corrections, see**  
**Bibliography INID code(s) 22**

(51) Int Cl.:

**C07K 16/28** <sup>(2006.01)</sup> **C12N 5/0735** <sup>(2010.01)</sup>  
**G01N 33/53** <sup>(2006.01)</sup> **A61K 35/12** <sup>(2015.01)</sup>  
**C12Q 1/02** <sup>(2006.01)</sup> **A61K 35/545** <sup>(2015.01)</sup>  
**G01N 33/50** <sup>(2006.01)</sup>

(48) Corrigendum issued on:

**21.03.2018 Bulletin 2018/12**

(43) Date of publication:

**31.01.2018 Bulletin 2018/05**

(21) Application number: **17188594.0**

(22) Date of filing: **06.03.2007**

(84) Designated Contracting States:

**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR**  
**HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE**  
**SI SK TR**

(30) Priority: **06.03.2006 US 778913 P**

(62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC:

**07716153.7 / 1 994 144**

(71) Applicant: **Agency for Science, Technology and Research**

**Singapore 138668 (SG)**

(72) Inventors:

- **CHOO, Andre**  
**Singapore 138668 (SG)**
- **OH, Steve**  
**Singapore 138668 (SG)**

(74) Representative: **Salisbury, Frances et al**

**Mewburn Ellis LLP**  
**City Tower**  
**40 Basinghall Street**  
**London EC2V 5DE (GB)**

Remarks:

This application was filed on 30.08.2017 as a divisional application to the application mentioned under INID code 62.

(54) **HUMAN EMBRYONIC STEM CELL METHODS AND PODXL EXPRESSION**

(57) A method of identifying an undifferentiated human embryonic stem cell in a sample which may contain such cells, the method comprising identifying the cell or cells within the sample that express podocalyxin-like protein (PODXL) on their surface. A method of isolating an undifferentiated human embryonic stem cell from a sample containing such cells, the method comprising isolating the cell or cells within the sample that express PODXL

on their surface. Typically, the methods use an antibody which binds to PODXL. Undifferentiated human embryonic stem cells isolated by the method may be useful in cell therapy. Also, in particular, compositions of cells differentiated from a human embryonic stem cell but which composition has been depleted of undifferentiated human embryonic stem cells are provided which are useful in cell therapy.

**EP 3 275 901 A8**